STING1 and liver disorder: Preclinical investigations include ALG-03104, which exhibits potent antitumor activity in murine models; INDP-010, capable of inducing systemic innate and adaptive immune activation across animal and human systems via intravenous delivery and approved by the U.S. FDA to enter clinical trials (190); and Licochalcone B (LicoB), which shows hepatoprotective and anti-hepatocarcinoma effects in HepG2 cells and CCl4-induced acute liver injury mice, suggesting new perspectives for STING modulation in liver diseases.